Conference Coverage
Conference Coverage
Switching to riociguat effective for some patients with PAH not at treatment goal
The clinical benefit of the switching to the sGC inhibitor was consistent across patient subgroups in the phase 4 REPLACE study.
Conference Coverage
Score predicts risk for ventilation in COVID-19 patients
“If mild COVID disease in young patients caused cardiac injury, you can imagine what it can do to older patients with severe disease,” Dr....
Conference Coverage
When should students resume sports after a COVID-19 diagnosis?
Conference Coverage
Data on potential risks of COVID-19 in psoriasis patients limited, but reassuring
For patients with psoriasis concerned about their outcome if infected with COVID-19, “there is no evidence to support stopping biologics or...
Conference Coverage
COVID-19: Convalescent plasma falls short in phase 2 trial
Convalescent plasma may reduce viral load, hospital stay, and mortality, but randomized controlled trials to date have ended prematurely.
Conference Coverage
Certain statins linked to lower mortality risk in patients admitted for sepsis
Statin use was associated with lower mortality, compared with no use, with hydrophilic and synthetic statins besting lipophilic and fungal-derived...
Conference Coverage
Cardiogenic shock rate soars in COVID-positive ACS
In-hospital mortality was quadrupled in COVID-positive STEMI patients.
Conference Coverage
Selexipag has no effect on daily activity in PAH patients
After 24 months of daily tracking, there was no benefit to increased daily activity for patients taking this drug.
Conference Coverage
COVID-19 experience forced residents to quickly improve patient communication skills
At the peak of the pandemic in New York City, goals of care discussions became easier, though coping with death remains an issue.
Conference Coverage
Experts tout immediate quadruple therapy for HFrEF patients
Recent evidence cemented four drug classes as foundational pillars of HFrEF treatment. The answer to how to start them: immediately and all at...
Conference Coverage
‘Modest’ benefit for post-MI T2D glucose monitoring
Equivocal results were seen with regard to the best method to monitor blood glucose after myocardial infarction.